First-in-human study of PSMA-targeting agent, [18F]AlF-P16-093: dosimetry and initial evaluation in prostate cancer patients

• Published in: European journal of nuclear medicine and molecular imaging Vol. 51; no. 6; pp. 1753 - 1762
• Main Authors: Zhao, Ruiyue, Ke, Miao, Lv, Jie, Liu, Shaoyu, Liu, Yuheng, Zhang, Jing, Xu, Lifu, Gu, Di, Li, Mingzhao, Cai, Chao, Liu, Yongda, Zeng, Guohua, Alexoff, David, Ploessl, Karl, Zhu, Lin, Kung, Hank F., Wang, Xinlu
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.05.2024; Springer Nature B.V
• Subjects: Cardiology; Dosimeters; Dosimetry; Fluorine isotopes; Imaging; Lesions; Lymph nodes; Medicine; Medicine & Public Health; Metastases; Metastasis; Nuclear Medicine; Oncology; Original Article; Orthopedics; Pharmaceuticals; Positron emission; Prostate cancer; Radiation; Radiochemistry; Radioisotopes; Radiology; Scanning; Soft tissues; Synthesis; Tumors; PSMA; PET/CT; F]AlF-P16-093; [; Dosimetry; Diagnosis; Prostate cancer; [18F]AlF-P16-093

Purpose This is a first-in-human study to evaluate the radiation dosimetry of a new prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical, [ 18 F]AlF-P16-093, and also initial investigation of its ability to detect PSMA-positive tumors using PET scans in a cohort of prostate cancer...